AstraZeneca
AstraZeneca’s Imfinzi misses target in Phase III head and neck cancer trial
February 5, 2021Medical Communications AstraZeneca, Cancer
AstraZeneca’s Imfinzi (durvalumab) has failed to improve overall survival (OS) for patients with recurrent or metastatic head and neck cancer …
China approves AstraZeneca’s heart failure drug Forxiga
February 4, 2021AstraZeneca, Forxiga
AstraZeneca’s Forxiga (dapagliflozin) has been approved for use in China to reduce the risk of death and hospitalisation from heart …
Longer Oxford-AstraZeneca vaccine interval improves efficacy, report says
February 3, 2021Research and Development AstraZeneca, COVID-19
A longer interval between doses of the Oxford University-AstraZeneca vaccine could substantially improve efficacy, according to a report published in …
AstraZeneca COVID-19 vaccine not for over 65s, German health body says
January 29, 2021Medical Communications AstraZeneca, COVID-19
Germany’s main public health body has recommended that AstraZeneca’s COVID-19 vaccine is only administered to those aged between 18 and …
AstraZeneca rejects “incorrect” claims about COVID-19 vaccine efficacy
January 26, 2021Manufacturing and Production AstraZeneca, COVID-19
AstraZeneca has rejected claims by German media that its COVID-19 vaccine has only 8% efficacy in over-65s. Two German newspapers, …
EU approves breast cancer drug Enhertu
January 20, 2021Research and Development AstraZeneca, Daiichi Sankyo
The EU has granted AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) conditional approval as a monotherapy for the treatment of …
AstraZeneca’s Imfinzi gets EU and UK approval for new dosing option
January 15, 2021Medical Communications AstraZeneca, Cancer, Imfinzi
AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU and the UK for an additional dosing option in locally advanced, …
AstraZeneca seeks EU approval for COVID-19 vaccine
January 12, 2021Manufacturing and Production AstraZeneca, COVID-19, Vaccine
AstraZeneca has applied for conditional marketing authorisation (CMA) from the EMA for its COVID-19 vaccine. CMA is used as the …
NICE recommends AstraZeneca’s FORXIGA for heart failure
January 7, 2021AstraZeneca, NICE
NICE has issued a positive Final Appraisal Document (FAD) recommending AstraZeneca’s FORXIGA (dapagliflozin) as an option for treatment of symptomatic …
AstraZeneca’s Farxiga granted Priority Review by FDA
January 6, 2021Research and Development AstraZeneca, FDA, farxiga
AstraZeneca’s Farxiga (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney …
UK becomes first country to roll out Oxford University-AstraZeneca COVID-19 vaccine
January 4, 2021Sales and Marketing AstraZeneca, COVID-19, Vaccine
The UK has become the first country to administer the Oxford University-AstraZeneca COVID-19 vaccine to its population as coronavirus case …
AstraZeneca’s cancer drug Tagrisso gets FDA approval
December 21, 2020Sales and Marketing AstraZeneca, Cancer, FDA
The FDA has approved AstraZeneca’s Tagrisso (osimertinib) for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated …
EMA panel recommends label extension of AstraZeneca’s Imfinzi in non-small cell lung cancer
December 15, 2020Manufacturing and Production, Sales and Marketing AstraZeneca, Europe, Imfinzi, NSCLC
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has backed a new dosing regimen of AstraZeneca’s …
AstraZeneca to buy Alexion in $39 billion deal
December 14, 2020Sales and Marketing Alexion, AstraZeneca, merger
British-Swedish AstraZeneca is set to acquire American biopharmaceutical company Alexion for $39 billion, in a move that will see a …
European approval for AstraZeneca’s Trixeo Aerospace in moderate to severe COPD
December 14, 2020Sales and Marketing AstraZeneca, COPD, EMA, Europe, Trixeo Aerosphere
The European Medicines Agency (EMA) has announced the approval of AstraZeneca’s Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) in the European Union …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
